Skip to search formSkip to main contentSkip to account menu

Doxorubicin-loaded EGFR-targeting Nanocells

Known as: EGFR-targeted EnGeneIC Dream Vectors Containing Doxorubicin, EGFR(V)-EDV-Dox, EGFR (Vectibix Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin 
A nanocell formulation targeting the epidermal growth factor receptor (EGFR) using bispecific antibodies (bsAb) against EGFR and containing the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Registr CORECT je neintervencni poregistreacni databaze zaměřena na sběr epidemiologických a klinických dat pacientů s diagnozou… 
2012
2012
Seit gezeigt werden konnte, dass bei Patienten mit metastasiertem kolorektalem Karzinom (mKRK)eine Mutation im KRAS-Gen mit einem… 
2011
2011
1 Le panitumumab est un anticorps monoclonal humain anti-EGFR. Il s'administre en perfusion intraveineuse et est indique en… 
2011
2011
In June 2011, the European Medicines Agency (EMA) extended the licensed indication for panitumumab (Vectibix®), a monoclonal… 
Review
2011
Review
2011
2010
2010
Despite data indicating that patients suffering from metastatic colorectal cancer with wild-type KRAS status might benefit from… 
2010
2010
QIAGEN (formerly DxS Ltd) has established itself as the market leader in the successful co-development of drug-diagnostic…